- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01365936
hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF
March 28, 2012 updated by: Figen Turkcapar, Zekai Tahir Burak Women's Health Research and Education Hospital
Influence of Ovarian Stimulation With hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF
There have been some controversies regarding the use of preparations with LH activity in patients with polycystic ovary syndrome (PCOS) who have high endogenous LH activity.
In this research we aimed to compare urinary menotrophin versus recombinant FSH (rFSH) with respect to the prevention of OHSS
Study Overview
Detailed Description
Polycystic ovary syndrome was diagnosed according to the Rotterdam criteria.
Patients older than 38 years or with serum FSH level ≥12mIU/ml and a history of ovarian surgery were excluded from the study.
All of our patients were given combined oral contraceptive (Yasmin) prior to ovulation induction cycles.
Leuprolide Acetate (Lucrin daily; Abbott, Istanbul) therapy was started in mid-luteal phase to induce pituitary down regulation, and was initiated at a dose of 1.0 mg SC daily until pituitary down-regulation was established.
The leuprolide acetate dose was then reduced to 0.5 mg daily until the day of human chorionic gonadotropin (hCG) administration.
After GnRH analogue suppression was achieved, the patients were randomized using block randomization (block of two) to stimulation with hMG (Menogon; Ferring Pharmaceuticals.
Istanbul) or rFSH (Gonal-F; Serono Istanbul).
Starting dose was 150IU for the first 3 days of stimulation, after which daily dosing was determined individually.
Serial Estrodiol (E2) levels and two-dimensional follicle measurements by transvaginal ultrasonography (LOGIC 200 PRO, General Electric, Korea) were performed until at least two dominant follicles reached dimensions of 18 mm or greater in diameter.
Human chorionic gonadotropin (Pregnyl, Organon, 10,000 IU- IM) was then administered, followed by transvaginal oocyte retrieval 36 hours later.
The criteria of coasting in our institute were serum E2 >3600 pg/ml and multiple intermediate follicle.
During coasting period, gonadotropin was withheld, but leuprolide acetate was continued at 0.5mg/d.
ICSI was performed for all the patients.
Fertilization was assessed at 20h (±1h), and embryo quality was assessed at 28, 44, and 68h (±1h) after oocyte retrieval.
A top- quality embryo was defined as four to five cells on day 2, seven or more cells on day 3, and no multinucleation.
Vaginal progesterone gel 90 mg/day 8% (Crinone;Serono) for luteal support was given from the oocyte retrieval until the clinical pregnancy (9-10 weeks of gestation) or negative serum βhCG test (13-15 days after embryo transfer).
Study Type
Interventional
Enrollment (Actual)
80
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ankara, Turkey
- Zekai Tahir Burak women's research and Training Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 38 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Women with PCOS
Exclusion Criteria:
- Patients older than 38 years or with serum FSH level ≥12mIU/ml and a history of ovarian surgery were excluded from the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: menotrophin
In this prospective trial, women with PCOS (according to Rotterdam criteria) were randomized (80 patients) after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
|
In this prospective trial, women with PCOS (according to Rotterdam criteria) were randomized (80 patients) after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
Other Names:
|
ACTIVE_COMPARATOR: recombinant FSH
Patients were randomized after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
|
Patients were randomized after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
the incidence of OHSS
Time Frame: 6 Months
|
6 Months
|
peak serum E2 levels
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
the need of coasting,
Time Frame: 6 months
|
6 months
|
number of intermediate follicles
Time Frame: 6 months
|
6 months
|
fertilization rate
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Figen A Turkcapar, MD, Zekai Tahir Burak Women's Health Research and Training Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2008
Primary Completion (ACTUAL)
June 1, 2008
Study Completion (ACTUAL)
June 1, 2008
Study Registration Dates
First Submitted
May 31, 2011
First Submitted That Met QC Criteria
June 2, 2011
First Posted (ESTIMATE)
June 3, 2011
Study Record Updates
Last Update Posted (ESTIMATE)
March 29, 2012
Last Update Submitted That Met QC Criteria
March 28, 2012
Last Verified
March 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZTBIVF1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polycystic Ovary Syndrome
-
Cairo UniversityCompleted
-
Alexandria UniversityRecruitingPolycystic Ovary Syndrome (PCOS)Egypt
-
Saudi German Hospital - MadinahCompletedPolycystic Ovary Syndrome (PCOS)Saudi Arabia
-
University of CopenhagenCompletedPolycystic Ovary Syndrome (PCOS)Denmark
-
Odense University HospitalCompleted
-
Poznan University of Medical SciencesUniversity of California, DavisUnknownPolycystic Ovary Syndrome (PCOS)Poland
-
Mansoura UniversityNot yet recruitingPCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
-
Assaf-Harofeh Medical CenterUnknownInfertility | Polycystic OvariesIsrael
-
Riphah International UniversityCompleted
-
Dexa Medica GroupCompletedPolycystic Ovary Syndrome (PCOS)Indonesia
Clinical Trials on HMG
-
LG ChemCompletedInfertility, FemaleKorea, Republic of
-
Instituto Valenciano de Infertilidad, IVI VALENCIACompleted
-
Ferring PharmaceuticalsFerring SAUCompleted
-
Ferring PharmaceuticalsFerring SAUCompleted
-
Alaa Fouli Gaber EbrahimUnknownOvarian Stimulation in ICSIEgypt
-
Ferring PharmaceuticalsFerring SAUCompleted
-
IBSA Institut Biochimique SACompleted
-
Ferring PharmaceuticalsFerring SAUCompleted
-
Fundació Institut de Recerca de l'Hospital de la...Programa de Reproducción Asistida F. Puigvert - HSCSPTerminatedPolycystic Ovary SyndromeSpain
-
Ferring PharmaceuticalsFerring SAUCompleted